Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications

Yu Liu, Jieyue Liao, Ming Zhao, Haijing Wu, Susan Yung, Tak Mao Chan, Akihiko Yoshimura, Qianjin Lu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The innate immune system has been shown to play an important pathologic role in systemic lupus erythematosus (SLE). TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecular patterns and has been implicated in the initiation and maintenance of the perpetuated inflammatory reactions in autoimmune diseases. Here, we report increased expression of TLR2 in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes from SLE patients. Conventional treatment, such as hydroxychloroquine and corticosteroids, showed no effect on TLR2 expression in CD4+ T cells from SLE patients. In vitro stimulation of TLR2 in CD4+ T cells from SLE patients increased CD40L and CD70 expression, as well as secretion of IL-6, IL-17A, IL-17F, and TNF-α, while Foxp3 transcription decreased. This effect was reversed by TLR2 siRNA. Moreover, TLR2 activation upregulated H3K4 tri-methylation and H4 acetylation levels while downregulated H3K9 tri-methylation level in the IL-17A promoter region. In addition, it also increased H4 acetylation levels and decreased H3K9 tri-methylation levels in the IL-17F promoter region. In summary, our findings demonstrate that increased expression of TLR2 contributes to immune reactivity and promotes IL-17A and IL-17F expression through histone modifications in SLE.

Original languageEnglish
Pages (from-to)2683-2693
Number of pages11
JournalEuropean Journal of Immunology
Volume45
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

Histone Code
Interleukin-17
Systemic Lupus Erythematosus
T-Lymphocytes
Methylation
Acetylation
Genetic Promoter Regions
Hydroxychloroquine
CD40 Ligand
Small Interfering RNA
Autoimmune Diseases
Monocytes
Immune System
Interleukin-6
Adrenal Cortex Hormones
B-Lymphocytes
Down-Regulation
Maintenance

Keywords

  • Histone modification
  • IL-17
  • Systemic lupus erythematosus
  • T cells
  • TLR2

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. / Liu, Yu; Liao, Jieyue; Zhao, Ming; Wu, Haijing; Yung, Susan; Chan, Tak Mao; Yoshimura, Akihiko; Lu, Qianjin.

In: European Journal of Immunology, Vol. 45, No. 9, 01.09.2015, p. 2683-2693.

Research output: Contribution to journalArticle

Liu, Yu ; Liao, Jieyue ; Zhao, Ming ; Wu, Haijing ; Yung, Susan ; Chan, Tak Mao ; Yoshimura, Akihiko ; Lu, Qianjin. / Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. In: European Journal of Immunology. 2015 ; Vol. 45, No. 9. pp. 2683-2693.
@article{dcde4365c91444a39dbd1d4bf86cb5cb,
title = "Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications",
abstract = "The innate immune system has been shown to play an important pathologic role in systemic lupus erythematosus (SLE). TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecular patterns and has been implicated in the initiation and maintenance of the perpetuated inflammatory reactions in autoimmune diseases. Here, we report increased expression of TLR2 in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes from SLE patients. Conventional treatment, such as hydroxychloroquine and corticosteroids, showed no effect on TLR2 expression in CD4+ T cells from SLE patients. In vitro stimulation of TLR2 in CD4+ T cells from SLE patients increased CD40L and CD70 expression, as well as secretion of IL-6, IL-17A, IL-17F, and TNF-α, while Foxp3 transcription decreased. This effect was reversed by TLR2 siRNA. Moreover, TLR2 activation upregulated H3K4 tri-methylation and H4 acetylation levels while downregulated H3K9 tri-methylation level in the IL-17A promoter region. In addition, it also increased H4 acetylation levels and decreased H3K9 tri-methylation levels in the IL-17F promoter region. In summary, our findings demonstrate that increased expression of TLR2 contributes to immune reactivity and promotes IL-17A and IL-17F expression through histone modifications in SLE.",
keywords = "Histone modification, IL-17, Systemic lupus erythematosus, T cells, TLR2",
author = "Yu Liu and Jieyue Liao and Ming Zhao and Haijing Wu and Susan Yung and Chan, {Tak Mao} and Akihiko Yoshimura and Qianjin Lu",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/eji.201445219",
language = "English",
volume = "45",
pages = "2683--2693",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "9",

}

TY - JOUR

T1 - Increased expression of TLR2 in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications

AU - Liu, Yu

AU - Liao, Jieyue

AU - Zhao, Ming

AU - Wu, Haijing

AU - Yung, Susan

AU - Chan, Tak Mao

AU - Yoshimura, Akihiko

AU - Lu, Qianjin

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The innate immune system has been shown to play an important pathologic role in systemic lupus erythematosus (SLE). TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecular patterns and has been implicated in the initiation and maintenance of the perpetuated inflammatory reactions in autoimmune diseases. Here, we report increased expression of TLR2 in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes from SLE patients. Conventional treatment, such as hydroxychloroquine and corticosteroids, showed no effect on TLR2 expression in CD4+ T cells from SLE patients. In vitro stimulation of TLR2 in CD4+ T cells from SLE patients increased CD40L and CD70 expression, as well as secretion of IL-6, IL-17A, IL-17F, and TNF-α, while Foxp3 transcription decreased. This effect was reversed by TLR2 siRNA. Moreover, TLR2 activation upregulated H3K4 tri-methylation and H4 acetylation levels while downregulated H3K9 tri-methylation level in the IL-17A promoter region. In addition, it also increased H4 acetylation levels and decreased H3K9 tri-methylation levels in the IL-17F promoter region. In summary, our findings demonstrate that increased expression of TLR2 contributes to immune reactivity and promotes IL-17A and IL-17F expression through histone modifications in SLE.

AB - The innate immune system has been shown to play an important pathologic role in systemic lupus erythematosus (SLE). TLR2, a PRR, recognizes exogenous PAMPs, and endogenous damage-associated molecular patterns and has been implicated in the initiation and maintenance of the perpetuated inflammatory reactions in autoimmune diseases. Here, we report increased expression of TLR2 in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes from SLE patients. Conventional treatment, such as hydroxychloroquine and corticosteroids, showed no effect on TLR2 expression in CD4+ T cells from SLE patients. In vitro stimulation of TLR2 in CD4+ T cells from SLE patients increased CD40L and CD70 expression, as well as secretion of IL-6, IL-17A, IL-17F, and TNF-α, while Foxp3 transcription decreased. This effect was reversed by TLR2 siRNA. Moreover, TLR2 activation upregulated H3K4 tri-methylation and H4 acetylation levels while downregulated H3K9 tri-methylation level in the IL-17A promoter region. In addition, it also increased H4 acetylation levels and decreased H3K9 tri-methylation levels in the IL-17F promoter region. In summary, our findings demonstrate that increased expression of TLR2 contributes to immune reactivity and promotes IL-17A and IL-17F expression through histone modifications in SLE.

KW - Histone modification

KW - IL-17

KW - Systemic lupus erythematosus

KW - T cells

KW - TLR2

UR - http://www.scopus.com/inward/record.url?scp=84940960375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940960375&partnerID=8YFLogxK

U2 - 10.1002/eji.201445219

DO - 10.1002/eji.201445219

M3 - Article

VL - 45

SP - 2683

EP - 2693

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 9

ER -